Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)
Phase: Phase II-III clinical trials
Principal Investigator: Prof. Mazzaferro Vincenzo
Main Facility: Chirurgia Generale Oncologica 1 – Epato-Gastro-Pancreatica e Trapianto di Fegato
Drug: Durvalumab E Tremelimumab
Pathologies: Hepatocellular carcinoma (HCC)
ClinicalTrials.gov: Read more about clinical trials
This is a multicenter, open-label, phase II study aimed at evaluating the safety, feasibility, and efficacy of perioperative immunotherapy with durvalumab and tremelimumab in patients with resectable hepatocellular carcinoma (HCC) eligible for surgery.
The study includes a neoadjuvant phase consisting of two cycles of treatment followed by surgical tumor resection. In the postoperative period, patients receive adjuvant treatment with durvalumab for up to 11 cycles.
The objective of the study is to assess the safety of the perioperative regimen and to determine whether this approach can enhance the anti-tumor immune response, reduce the risk of recurrence, and improve clinical outcomes in patients undergoing resection.
Last update: 20/04/2026